In this episode of the Oncology Brothers podcast, Dr. Mark Lewis joins as a guest to discuss key studies in GI malignancies from ASCO 2024. The episode covers significant updates from the ESOPEC trial comparing concurrent chemoradiation with periopflot for upper GI adenocarcinoma.
• The ESOPEC study comparing concurrent chemoradiation versus periopflot for upper GI adenocarcinoma.
• The ARMANI trial on switch maintenance with bramicerumab plus paclitaxel.
• The TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer.
• The COLLISION trial comparing surgery versus ablation for small size colorectal liver metastatic disease.
• The COMET study looking at the use of atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer.
The ARMANI trial on switch maintenance with bramicerumab plus paclitaxel is also discussed, along with the TRANSMET trial exploring chemotherapy followed by liver transplantation for metastatic liver-confined colorectal cancer. The Collision trial comparing surgery versus ablation for small size colorectal liver metastatic disease and the COMET study looking at atezolizumab with chemotherapy in first-line treatment for MSI high metastatic colorectal cancer are also highlighted. The importance of biomarker testing and a multidisciplinary approach in oncology treatment is emphasized throughout the discussion. Overall, the episode provides valuable insights into the latest advancements in GI oncology and the evolving treatment landscape for patients with gastrointestinal malignancies.
